391 reports of this reaction
1.9% of all POSACONAZOLE DELAYED RELEASE reports
#10 most reported adverse reaction
THROMBOCYTOPENIA is the #10 most commonly reported adverse reaction for POSACONAZOLE DELAYED RELEASE, manufactured by A2A Integrated Pharmaceuticals. There are 391 FDA adverse event reports linking POSACONAZOLE DELAYED RELEASE to THROMBOCYTOPENIA. This represents approximately 1.9% of all 20,089 adverse event reports for this drug.
Patients taking POSACONAZOLE DELAYED RELEASE who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is a less commonly reported adverse event for POSACONAZOLE DELAYED RELEASE, but still significant enough to appear in the safety profile.
In addition to thrombocytopenia, the following adverse reactions have been reported for POSACONAZOLE DELAYED RELEASE:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 391 FDA reports for POSACONAZOLE DELAYED RELEASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 1.9% of all adverse event reports for POSACONAZOLE DELAYED RELEASE, making it a notable side effect.
If you experience thrombocytopenia while taking POSACONAZOLE DELAYED RELEASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.